Kanilad (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilises hyper‑excitable neuronal membranes. It also binds to CRMP2, a protein involved in neuronal signalling, thereby reducing the spread of epileptic discharges without suppressing normal brain activity.

The dosage of Kanilad is individualised by the prescribing clinician based on the patient’s age, weight, renal function and response to therapy. Physicians start with a low dose and may titrate upward to achieve optimal seizure control while monitoring for side effects.

Safety data for lacosamide during pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To request Kanilad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, lacosamide has a distinct mechanism that enhances slow inactivation rather than fast inactivation, offering a different side‑effect profile. It is generally well tolerated and may be preferred when patients experience intolerable side effects from other agents, though individual response varies.

Kanilad should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Kanilad is taken orally. The tablet should be swallowed whole with a glass of water and can be taken with or without food, as directed by the prescriber. Consistency in the time of day helps maintain stable blood levels.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and emergence of suicidal thoughts or behaviours. Patients should seek immediate medical attention if they notice palpitations, rash, or mood changes.

Kanilad is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients. Caution is advised for individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, and those taking other medications that markedly affect cardiac rhythm or sodium‑channel function.